Commentary

With eDiscovery, the benefits of a written document retention policy and a formal review process are many, according to Michael Best & Friedrich attorney John Flanagan. In this third in a four-part series on e-discovery, a new mandate that companies are struggling with, Flanagan explains...

Everybody wants to hype the latest “discovery” made possible by stem-cell research, but columnist Tom Still states that these revelations must be accompanied by perspective. In this edition of Inside Wisconsin, he notes that stem-cell research offers hope that science will learn more until diagnostics,...

Ever wonder why so many people can't find good-paying jobs in IT and other fields? In this edition of Carlini's Comments, James Carlini charges that some American employers are selling out their country by shutting qualified Americans out of the hiring process in favor of...

After a rather lackluster first quarter, the overall stock market surged back in Q2, and life science stocks continued their torrid pace, according to columnist Michael Rosen. In this edition of Yer Biotech Blues, he chronicles who's hot, who's not so hot, and the prospects...

The shopping dance known as online retailing keeps adding and modifying steps, making it hard for partners to find their rhythm, according to columnist Paul Gibler. In this edition of Buzz Networks, he describes the retail transformation taking place through a range of Internet...

In the age of digital everything, a creative website offers proof that print still captures the imagination of consumers, even the most loyal devotees of the Internet. In this edition of DEMO Letter, columnist Chris Shipley toasts Eileen Gittens, the founder of Blurb, the book-creation...

The biofuels revolution is not only beneficial for agriculture, natural resources, and national security, it could potentially have a reform dimension, according to columnist Tom Still. Touting a bill introduced by Wisconsin Congressman Ron Kind, he writes in this edition of Inside Wisconsin that biofuels...

Early-stage companies can benefit from having an Advisory Board of people who have “been there and done that,” but the trick is using their expertise effectively. In this guest column on building a team of advisors, Michael Best and Friedrich attorney William Robinson shares some...

When it comes to approving drugs in the United States, should safety be the primary endpoint for approval? In this second part of a MedTech Futures column on the FDA approval process, Dr. Ogan Gurel calls for the FDA to refocus its primary mission on...